Trial results

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

NCT07614412 on ClinicalTrials.gov · last registry update 2026-05-29

An unusually large phase 2: 240 participants, more than double the 114 typical for the stage. Due to report 31 January 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Change in 2-hour stimulated C-peptide Area Under the Curve (AUC) during a Mixed Meal Tolerance Test (MMTT). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Ministry of Health, Saudi Arabia

Sponsor type

Other Gov

Enrollment

240

Started

2027-01-01

Primary completion

2028-01-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in 2-hour stimulated C-peptide Area Under the Curve (AUC) during a Mixed Meal Tolerance Test (MMTT)

Conditions studied

Type 1 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.